Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Estey
E H
EH
Department of Hematology, University of Texas, M. D. Anderson Cancer Center, Houston 77030.
Plunkett
W
W
Kantarjian
H
H
Rios
M B
MB
Keating
M J
MJ
D000328:Adult; D000368:Aged; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism*; D002985:Clinical Protocols; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction
D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate